NEO Alternatives Receives Special Permit, Paving the Way Towards Construction of First Production Facility

Share Article

Authorization Brings Brand One Step Closer to Autonomy in Production Process of Cannabis Product Assortment.

NEO Alternatives

"I am excited to be at the forefront of NEO’s launch into the Massachusetts Cannabis Market. We look forward to introducing a science-based cannabis product line, while creating an empowerment space for women to further the advancement of the Cannabis Industry as a whole," said Jaime Lewis, NEO EVP

NEO Alternatives, a U.S. based company reshaping the CBD and Cannabis wellness category, today announces receipt of a special permit in the town of Medway, MA granting the company the ability to obtain licenses for cultivating and manufacturing Cannabis products within the state.

In a recent unanimous vote, Board Members in the town of Medway granted NEO a Special Permit, marking the last in a series of milestones needed by NEO to complete pre-provisional licensing. This vertical will enable NEO to tightly control their chain of custody for better research and development of property products. This will also allow NEO to execute licensing agreements with leading extraction and cultivation firms, as well as continue growing their brand portfolio, through strategic partnerships that align with their company goals of creating highly effective, sustainable products in the health and wellness space.

Once granted approval of application completion by the Cannabis Control Commission (CCC), a provisional license will follow within 90 days. While these processes are underway, NEO plans on moving forward with the final design and engineering stages of their 29,000 sq. ft. state-of-the-art facility with full-scale production scheduled for commencement in early summer 2020.

“I am excited to be at the forefront of NEO’s launch into the Massachusetts Cannabis Market,” said Jaime Lewis, Executive Vice President of NEO Alternatives. Lewis previously served three terms as the Chairwoman of the National Cannabis Industry Association and is a member of the Massachusetts Cannabis Commission’s Advisory Board. “As a female pioneer in the Cannabis Industry, I have had the opportunity to work in many new emerging markets throughout the US. Having had to prove myself over and over throughout the years, has pushed me to excel and expand my vision.” She continues, “NEO is the culmination of these efforts and we look forward to introducing a science-based cannabis product line as well as creating an empowerment space for women to further the advancement of the Cannabis Industry as a whole.“

Once the facility buildout and redesigns are completed, NEO will begin the cultivation and production process with a focus on topicals and edibles, utilizing certified organic medical plants for their high-quality blends and recipes.

For more information on NEO Alternatives, please visit: http://www.neoalts.com

To schedule an interview with a senior member of the NEO Alternatives team, please contact Adam McCollum (adam@arm-communications.com / (213) 394-6688).

# # #

About NEO Alternatives
NEO Alternatives (NEO) is an innovative health and wellness company focused on redefining and elevating the Cannabis and CBD ecosphere. As a trailblazer and category disruptor, NEO’s portfolio of superior, premium-grade consumer brands and production facilities are at the forefront of defining the future of the cannabis and hemp industry. All NEO brands and products follow state-of-the-art agricultural practices while the company’s endeavors are also designed around strict protocols mandating the highest standards in production. These mandates include organic sourcing that follows sustainable, ethical, and eco-sensitive procedures; using natural and effective ingredients while also employing third-party testing and validation. NEO’s management team is comprised of industry leaders from the worlds of Cannabis, advertising, marketing, branding, finance and sales. For more information, please visit: http://www.neoalts.com

# # #

FDA Disclaimer: These products and statements have not been evaluated by the Food & Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Adam McCollum